Neuronal death is the ultimate consequence of Alzheimer's disease (AD) pathogenesis, responsible for the progressive brain atrophy and cognitive decline that defines the disease. The AD brain loses an estimated 100 million neurons during disease progression, with preferential loss in the hippocampus, entorhinal cortex, basal forebrain cholinergic neurons, and cortical association areas.
Although the exact mechanisms of neuronal death in AD remain debated, research has identified multiple regulated cell death pathways that contribute, including apoptosis, necroptosis, ferroptosis, pyroptosis, and parthanatos. Critically, these pathways do not act in isolation — they intersect and amplify each other, driven by upstream triggers including amyloid-beta toxicity, tau pathology, neuroinflammation, mitochondrial dysfunction, oxidative stress, and excitotoxicity. Understanding these cell death pathways is essential for developing neuroprotective therapies that could slow or halt neurodegeneration.
A fundamental feature of AD is that neuronal death is not uniform across the brain. Certain neuronal populations are selectively vulnerable:
- Hippocampal CA1 neurons: Among the first neurons lost, explaining early memory deficits. Vulnerability relates to high metabolic demand, calcium signaling, and exposure to both Aβ and tau pathology
- Entorhinal cortex layer II neurons: The origin of tau pathology in Braak staging, these neurons project to the hippocampus and are lost early in disease
- Basal forebrain cholinergic neurons: Loss of these neurons causes cholinergic deficits targeted by acetylcholinesterase inhibitors (e.g., donepezil, rivastigmine)
- Locus coeruleus noradrenergic neurons: Among the earliest neurons affected; noradrenergic loss may contribute to neuroinflammation and reduce Aβ clearance
- Layer 5 cortical pyramidal neurons: Large projection neurons in association cortex are preferentially affected
This selective vulnerability is thought to arise from a combination of high metabolic demand, intense calcium signaling, long unmyelinated axons, and network-level exposure to spreading pathological proteins.
The intrinsic apoptotic pathway is triggered by cellular stress signals converging on mitochondria:
- Mitochondrial outer membrane permeabilization (MOMP): Pro-apoptotic Bcl-2 family proteins (Bax, Bak) are activated by cellular stress signals including Aβ-induced oxidative damage and calcium overload. Bax/Bak oligomerize to form pores in the outer mitochondrial membrane
- Cytochrome c release: Cytochrome c escapes into the cytoplasm and binds Apaf-1 to form the apoptosome
- Caspase cascade: The apoptosome activates caspase-9, which cleaves and activates executioner caspases (caspase-3, caspase-7), leading to DNA fragmentation, chromatin condensation, and cell shrinkage
In AD, Aβ oligomers interact directly with mitochondria, disrupting Complex IV activity and promoting reactive oxygen species generation, which triggers MOMP. Tau hyperphosphorylation also impairs mitochondrial dynamics by disrupting DRP1-mediated fission and mitophagy.
The extrinsic pathway is activated by extracellular ligands binding to death receptors (Fas, TNF-R1, TRAIL-R):
- TNF-α signaling: Microglia-derived TNF-α can activate neuronal TNF-R1, triggering caspase-8 and the extrinsic apoptotic cascade
- Fas ligand: Fas-FasL interactions induce apoptosis in vulnerable neuronal populations
- TRAIL: TNF-related apoptosis-inducing ligand contributes to neuronal loss in AD
Necroptosis is a programmed form of necrotic cell death mediated by receptor-interacting protein kinases RIPK1 and RIPK3:
- Activation: TNF-α or other death receptor ligands activate RIPK1
- Complex formation: RIPK1 recruits and phosphorylates RIPK3, forming the necrosome
- MLKL phosphorylation: RIPK3 phosphorylates MLK (mixed lineage kinase domain-like), causing its oligomerization and translocation to the plasma membrane
- Membrane disruption: MLKL pores cause ionic imbalance, swelling, and necrotic cell death
- RIPK1 and RIPK3 are elevated in AD brain tissue, particularly in neurons showing granulovacuolar degeneration (GVD)
- Necroptosis markers accumulate in GVD vesicles, structures that are abundant in AD hippocampal neurons
- Necroptosis correlates with tau pathology more strongly than with amyloid plaque burden, suggesting tau is the proximate trigger
- Necroptosis releases DAMPs (damage-associated molecular patterns) that activate microglia
Ferroptosis is an iron-dependent form of regulated cell death driven by lethal lipid peroxidation:
- Iron accumulation: Excess labile iron catalyzes Fenton reactions, generating hydroxyl radicals
- Lipid peroxidation: Reactive oxygen species attack polyunsaturated fatty acids (PUFAs) in cell membranes, producing lipid hydroperoxides
- GPX4 failure: Glutathione peroxidase 4 (GPX4) normally reduces lipid peroxides to harmless lipid alcohols; when GPX4 is inactivated (by glutathione depletion or direct inhibition), lipid peroxidation cascades unchecked
- Membrane damage: Accumulated lipid peroxides compromise membrane integrity, causing cell death
Multiple lines of evidence implicate ferroptosis in AD neuronal death:
- Brain iron elevation: Iron accumulates in AD-affected regions, particularly the hippocampus and cortex, often co-localizing with amyloid plaques
- Lipid peroxidation markers: 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA) are elevated in AD brain
- Glutathione depletion: Reduced glutathione (GSH) levels decline in AD brain
- GPX4 alterations: GPX4 expression is reduced in AD-vulnerable neurons
- Aβ-iron interaction: Aβ binds iron and copper, generating reactive oxygen species through redox cycling and potentially nucleating ferroptotic death
- Iron chelators: Deferiprone has shown preliminary neuroprotective effects in AD models
- Lipophilic antioxidants: Vitamin E (α-tocopherol) and ferrostatin-1 analogs can inhibit lipid peroxidation
- GPX4 activators: Selenium supplementation and GPX4-enhancing strategies are under investigation
- NLRP3 activation by Aβ: Fibrillar Aβ is a potent activator of the NLRP3 inflammasome in microglia, driving chronic IL-1β release
- Neuronal pyroptosis: While initially described in microglia, neuronal pyroptosis via NLRP1 and caspase-1 has been demonstrated in AD models
- Feed-forward inflammation: Released IL-1β and IL-18 amplify neuroinflammation, further activating NLRP3
- NLRP3 as therapeutic target: NLRP3 inhibitors (e.g., MCC950/CRID3) reduce neuroinflammation and improve cognitive outcomes in AD mouse models
Aβ triggers neuronal death through multiple convergent mechanisms:
- Calcium dysregulation: Aβ oligomers form calcium-permeable pores in neuronal membranes and enhance NMDA receptor activation, causing excitotoxic calcium influx
- Synaptic dysfunction: Oligomers bind to prion protein (PrPC), mGluR5, and other synaptic receptors, impairing long-term potentiation and promoting long-term depression
- Mitochondrial toxicity: Aβ accumulates in mitochondria via TIM/TOM import machinery, inhibiting Complex IV and promoting reactive oxygen species generation
- Oxidative stress: Aβ-metal complexes (Cu²⁺, Fe³⁺, Zn²⁺) generate reactive oxygen species through Fenton chemistry
Tau pathology is a more proximate driver of neuronal death than amyloid:
- Microtubule destabilization: Hyperphosphorylated tau detaches from microtubules, disrupting axonal transport
- Tau oligomer toxicity: Soluble tau oligomers are synaptotoxic and can propagate between connected neurons in a prion-like manner
- Activation of cell death pathways: Tau triggers necroptosis (via GVD), activates caspases (caspase-6 cleaves tau, generating toxic fragments), and impairs autophagy
- Correlation with cognitive decline: Neurofibrillary tangle burden (Braak stage) is the strongest pathological correlate of cognitive impairment in AD
Chronic neuroinflammation drives neuronal death through:
- Microglial neurotoxicity: Chronically activated microglia produce pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) that are directly toxic to neurons
- Complement-mediated synaptic elimination: C1q and C3 tag synapses for microglial phagocytosis, and this "synaptic stripping" is aberrantly activated in AD
- Astrocyte dysfunction: Reactive astrocytes lose their neurotrophic and metabolic support functions while gaining neurotoxic properties (A1 phenotype)
- TREM2 and disease-associated microglia: TREM2 variants affect microglial response and disease progression
| Target |
Strategy |
Status |
| RIPK1 inhibitors |
Block necroptosis pathway |
Clinical trials (SAR443820) |
| Iron chelators |
Reduce iron-dependent lipid peroxidation |
Preclinical/Phase II |
| GPX4 activators |
Enhance lipid peroxide detoxification |
Preclinical |
| NLRP3 inhibitors |
Block inflammasome activation |
Preclinical |
| Anti-TNF-α |
Reduce neuroinflammation |
Preclinical |
| Caspase inhibitors |
Block apoptotic cascade |
Preclinical |